Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors

Journal of Medicinal Chemistry

Volumn 46, Issue 15, 2003, Pages 3333-3341

  Olesen, Preben H ^a   Sørensen, Anders R ^a   Ursø, Birgitte ^a   Kurtzhals, Peter ^a   Bowler, Andrew N ^a   Ehrbar, Ulrich ^a   Hansen, Bo F ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; ADENOSINE TRIPHOSPHATE; BETA CATENIN; CARBOXYLIC ACID DERIVATIVE; CHEMICAL COMPOUND; CHIR 98023; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INSULIN; MALEIMIDE DERIVATIVE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CELL ASSAY; CELL MEMBRANE PERMEABILITY; COMPARATIVE STUDY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG POTENCY; ENZYME ASSAY; ENZYME ISOLATION; GLYCOGEN METABOLISM; GLYCOGEN SYNTHESIS; IC 50; IN VITRO STUDY; INHIBITION KINETICS; NONHUMAN; RAT; SOLEUS MUSCLE; STRUCTURE ACTIVITY RELATION;

ANIMALS; BETA CATENIN; CHO CELLS; CRICETINAE; CYTOSKELETAL PROTEINS; DATABASES, FACTUAL; ENZYME INHIBITORS; GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MUSCLE, SKELETAL; OXADIAZOLES; RATS; RATS, WISTAR; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATORS; TRIAZOLES; WATER;

EID: 0037817456     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm021095d     Document Type: Article

References (23)

1. Coghlan, M. P.; Culbert, A. A.; Cross, D. A. E.; Corcoran, S. L.; Yates, J. W.; Pearce, N. J.; Rausch, O. L.; Murphy, G. J.; Carter, P. S.; Cox, L. R.; Mills, D.; Brown, M. J.; Haigh, D.; Ward, R. W.; Smith, D. G.; Murray, K. J.; Reith, A. D.; Holder, J. C. Selective small molecule inhibitors ofglycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. (London) 2000, 7, 793-803.
2. Cohen, P.; Frame, S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2001, 2, 769-776.
3. Weston, C. R.; Davis, R. J. Signaling Specificity- a Complex Affair. Science 2001, 292, 2439-2440.
4. Anderton, B. H.; Dayanandan, R.; Killick, R.; Lovestone, S. Does dysregulation of the Notch and wingless/Wnt pathways underlie the pathogenesis of Alzheimer's disease? Mol. Med. Today 2000, 6, 54-59.
5. Nikoulina, S. E.; Ciaraldi, T. P.; Abrams-Carter, L.; Mudaliar, S.; Park, K. S.; Henry, R. R. Regulation of glycogen synthase activity in cultured skeletal muscle cells from subjects with type II diabetes: role ofchronic hyperinsulinemia and hyperglycemia. Diabetes 1997, 46, 1017-1024.
6. Eldar-Finkelman, H.; Schreyer, S. A.; Shinohara, M. M.; LeBoeuf, R. C.; Krebs, E. G. Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. Diabetes 1999, 48, 1662-1666.
7. Eldar-Finkelman, H. Glycogen synthase kinase 3: An emerging therapeutic target. Trends Mol. Med 2002, 8, 126-132.
8. Cline, G. W.; Johnson, K.; Regittnig, W.; Perret, P.; Tozzo, E.; Xiao, L.; Damico, C.; Shulman, G. I. Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. Diabetes 2002, 51, 2903-2910.
9. Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Biernat, J.; Wu, Y. Z.; Mandelkow, E. M.; Eisenbrand, G.; Meijer, L. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease - A property common to most cycline-dependent kinase inhibitors? J. Biol. Chem. 2001, 276, 251-260.
10. Leost, M.; Schultz, C.; Link, A.; Wu, Y. Z.; Biernat, J.; Mandelkow, E. M.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Zaharevitz, D. W.; Gussio, R.; Senderowicz, A. M.; Sausville, E. A.; Kunick, C.; Meijer, L. Paullones are potent inhibitors of glycogen synthase kinase-3 beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 2000, 267, 5983-5994.
11. Smith, D. G.; Buffet, M.; Fenwick, A. E.; Haigh, D.; Ife, R. J.; Saunders: M.; Slingsby, B. P.; Stacey, R.; Ward, R. W. 3-anilino-4-arylmaleimides: Potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 2001, 11, 635-639.
12. Meijer, L.; Thunnissen, A. M. W. H.; White, A. W.; Garnier, M.; Nikolic, M.; Tsai, L. H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y. Z.; Biernat, J.; Mandelkow, E. M.; Kim, S. H.; Pettit, G. R. Inhibition of cyclin-dependent kinases, GSK-3 beta and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 2000, 7, 51-63.
13. Bowler, A. N., Engelhardt, S, Sørensen, A. R., Ursø, B, Bödvarsdóttir, T. B., Worsaae, H., Hansen, B. F., and Kutzhalz, P. 2,4-Diaminothiazoles: a Novel class of Glycogen Synthase Kinase-3 (GSK-3) Inhibitors. Presented at the 11th RSC-SCI Medicinal Chemistry Symposium, September 9-12, 2001, Cambridge, UK.
14. Naerum, L.; Norskov-Lauritsen, L.; Olesen, P. H. Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 1525-1528.
15. Martinez, A.; Castro, A.; Dorronsoro, I.; Alonso, M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 2002, 22, 373-384.
16. Martinez, A.; Alonso, M.; Castro, A.; Perez, C.; Moreno, F. J. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3 beta) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 2002, 45, 1292-1299.
17. Tselinskii, I. V.; Mel'nikova, S. F.; Vergizov, S. N. Azidofurazans in the synthesis of condensed systems. J. Org. Chem. USSR (Engl. Transl.) 1981, 17, 994-995.
18. Zelenin, A. K.; Trudell, M. L. A 2-step synthesis of diaminofurazan and synthesis of N- monoarylmethyl and N,N-1-diarylmethyl derivatives. J. Heterocycl. Chem. 1997, 34, 1057-1060.
19. Kubota, S.; Koida, Y.; Kosaka, T.; Kirino, O. Studies on the Synthesis of 1,3,4-Thiadiazole Derivatives. II. Synthesis of 1,3,4-Thiadiazoline-5-thiones from Amidrazones and Carbon Disulfide. Chem. Pharm. Bull. 1970, 18, 1696-1698.
20. Hanks, S. K.; Hunter, T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 1995, 9, 576-596.
21. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351, 95-105.
22. Hansen, B. F.; Danielsen, G. M.; Drejer, K.; Sørensen, A. R.; Wiberg, F. C.; Klein, H. H.; Lundemose, A. G. Sustained signaling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem. J. 1996, 315 (Pt 1), 271-279.
23. Olsen, G. S.; Hansen, B. F. AMP kinase activation ameliorates insulin resistance induced by free fatty acids in rat skeletal muscle. Am J Physiol Endocrinol. Metab. 2002, 283, E965-E970.